This article was originally published in The Tan Sheet
UPM Pharmaceuticals has agreed to manufacture SCOLR Pharma's controlled delivery technology (CDT) 24-hour OTC pseudoephedrine, SCOLR announces June 6. The Bellevue, Wash.-based firm says it plans to use the UPM-produced PSE tablets in studies to support an NDA, to be submitted to FDA in 2006. UPM also will produce several of SCOLR's other products currently in development, including CDT 12-hour ibuprofen, 12-hour pseudoephedrine and a CDT-based osteoporosis drug raloxifene (Eli Lilly's Evista). Clinical testing has already been initiated for the 12-hour ibuprofen, the company reports...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.